KMD Bioscience Conducts Literature Analysis | Object: HPV Antibody

Date：2025-11-19

The study “Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines” provides an in-depth comparison of the immunogenic responses elicited by the bivalent (Cervarix) and quadrivalent (Gardasil) HPV vaccines. The research focuses on the generation of neutralizing antibodies (NAbs) against both vaccine-included HPV types and non-vaccine HPV types, offering insights into each vaccine’s potential for broader protection.

Study Design and Methodology

The researchers conducted an independent comparison of NAb levels seven months after the initiation of three-dose, six-month vaccination schedules. The study involved adolescent females from Finland and India who received either the bivalent or quadrivalent HPV vaccine. A semi-automated Pseudovirion-Based Neutralization Assay was employed to measure NAb levels against HPV types 6, 16, 18, 31, 33, 45, 52, and 58.

Key Findings

Neutralizing Antibody Levels for Vaccine HPV Types:

HPV16 and HPV18: Recipients of the bivalent vaccine exhibited significantly higher peak NAb levels against HPV16 and HPV18 compared to those who received the quadrivalent vaccine.

Cross-Neutralizing Antibody Levels for Non-Vaccine HPV Types:

HPV31, HPV33, HPV45, HPV52, and HPV58: The bivalent vaccine induced cross-neutralizing antibodies against these non-vaccine HPV types more frequently and at higher levels than the quadrivalent vaccine.

Correlation of Antibody Levels:

HPV45 with HPV16/18: A stronger correlation was observed between NAb levels for HPV45 and HPV16/18 in bivalent vaccine recipients compared to quadrivalent vaccine recipients, suggesting a qualitatively different cross-reactive immune response.

Implications

The findings indicate that the bivalent vaccine not only induces robust immunity against its target HPV types (16 and 18) but also offers enhanced cross-protection against several non-vaccine HPV types associated with cervical cancer. This broader immunogenic profile could have significant implications for cervical cancer prevention strategies. However, the study’s authors note that the comparison was conducted in different populations (Finnish and Indian adolescents), highlighting the need for further head-to-head studies to confirm these results.

Conclusion

This study underscores the superior immunogenicity of the bivalent HPV vaccine in inducing both neutralizing and cross-neutralizing antibodies compared to the quadrivalent vaccine. These insights are crucial for informing vaccination policies and optimizing strategies for cervical cancer prevention.

Our Humanized HPV Antibody Products

Cat#	Product Name	Species	Host	Applications	Size	Price
MA2624	Humanized Anti-HPV6/HPV11/HPV33 mAb	HPV6/HPV11/HPV33	CHO		100ug, 500ug, 1mg	Inquiry
MA2625	Humanized Anti-HPV18/HPV45 mAb	HPV18/HPV45	CHO		100ug, 500ug, 1mg	Inquiry
MA2626	Humanized Anti-HPV16/HPV31/HPV52/HPV58 mAb	HPV16/HPV31/HPV52/HPV58	CHO		100ug, 500ug, 1mg	Inquiry